Table Graph
      published meta-analysis   sensitivity analysis   studies

favipiravir in COVID-19 (hospitalized or not) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias clinical improvementdetailed resultsChang Chen et al., 2020 1.48 [0.88; 2.48] 1.48[0.88; 2.48]Chang Chen et al., 202010%236NAnot evaluable clinical improvement (7-day)detailed resultsChang Chen et al., 2020 1.48 [0.88; 2.48] 1.48[0.88; 2.48]Chang Chen et al., 202010%236NAnot evaluable radiologic improvement (14-day)detailed resultsHong Zhao, 2021 (REV) 0.32 [0.06; 1.61] 0.32[0.06; 1.61]Hong Zhao, 2021 (REV)10%12NAnot evaluable serious adverse eventsdetailed resultsHong Zhao, 2021 (REV) 0.69 [0.01; 41.78] 0.69[0.01; 41.78]Hong Zhao, 2021 (REV)10%12NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-05-03 05:27 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 87 - treatments: 513 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons